Internal Medicine

George J. Weiner, MD


Director, Holden Comprehensive Cancer Center
Professor of Internal Medicine  - Hematology, Oncology and Blood and Marrow Transplantation

Contact Information

Primary Office: 5970-Z JPP
Iowa City, IA 52242
Phone: 319-353-8395

Web: Weiner Translational Research Laboratory
Web: Holden Comprehensive Cancer Center
Web: Video remarks
Web: The Expertise within Holden Comprehensive Cancer Center (Video)
Web: Big Ten Cancer Research Consortium (Video)
Web: The University of Iowa Holden Comprehensive Cancer Center (Video)
Web: Health at Iowa - Cancer DNA therapies (Video)
Web: Holden Comprehensive Cancer Center - University of Iowa Hospitals and Clinics (Video)


BA, Johns Hopkins University
MD, The Ohio State University

Residency, Internal Medicine, Medical College of Ohio
Fellowship, Hematology and Oncology, University of Michigan

Licensure and Certifications

Subspecialty Board in Hematology, ABIM
Subspecialty Board in Medical Oncology, ABIM
American Board of Internal Medicine
National Board of Medical Examiners

Education/Training Program Affiliations

Interdisciplinary Graduate Program in Immunology
Interdisciplinary Graduate Program in Informatics
Interdisciplinary Graduate Program in Translational Biomedicine
Medical Scientist Training Program

Research Summary

Dr. Weiner’s research focuses on understanding the mechanisms of action of anti-cancer monoclonal antibodies, and on development of novel approaches to immunotherapy of lymphoma. He has been continually funded by the NCI since 1991 and has been the PI on the University of Iowa / Mayo Clinic Lymphoma Specialized Program of Research Excellence (P50 CA097274) since it was initiated in 2002. This grant was renewed competitively in 2007 and 2012. Dr. Weiner’s research extends from basic laboratory investigation to clinical trials. He was the first to demonstrate Toll Like Receptor 9 agonists could be used successfully as immune adjuvants in tumor immunization. He has made major contributions to our understanding of the mechanisms of action responsible for the anti-tumor activity of monoclonal antibodies, including providing evidence that, in some cases, complement can inhibit the efficacy of some monoclonal antibodies. He has established a number of collaborative research programs, including working with Dr. Aliasger Salem from the UI College of Pharmacy on novel uses of nanoparticles to enhance the anti-tumor immune response.

Date Last Modified: 06/06/2016 - 13:17:48